Landscape Capital Management L.L.C. Takes $1.09 Million Position in Smith & Nephew SNATS, Inc. $SNN

Landscape Capital Management L.L.C. acquired a new position in Smith & Nephew SNATS, Inc. (NYSE:SNN) during the second quarter, Holdings Channel reports. The firm acquired 17,377 shares of the medical equipment provider’s stock, valued at approximately $1,090,000.

Several other institutional investors have also modified their holdings of SNN. Clearstead Trust LLC bought a new position in Smith & Nephew SNATS during the second quarter valued at about $25,000. Addison Advisors LLC bought a new stake in Smith & Nephew SNATS in the second quarter worth about $43,000. Allworth Financial LP bought a new stake in Smith & Nephew SNATS in the second quarter worth about $48,000. Garner Asset Management Corp acquired a new stake in Smith & Nephew SNATS in the 4th quarter valued at about $27,000. Finally, Arax Advisory Partners lifted its holdings in Smith & Nephew SNATS by 142.6% in the 4th quarter. Arax Advisory Partners now owns 968 shares of the medical equipment provider’s stock valued at $32,000 after acquiring an additional 569 shares during the last quarter. Institutional investors and hedge funds own 25.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on the stock. JPMorgan Chase & Co. restated a “neutral” rating on shares of Smith & Nephew SNATS in a research report on Thursday, August 6th. Zacks Research lowered shares of Smith & Nephew SNATS from a “hold” rating to a “strong sell” rating in a research note on Friday, August 7th. Canaccord Genuity Group reduced their target price on shares of Smith & Nephew SNATS from $32.00 to $30.00 and set a “hold” rating for the company in a report on Monday, May 11th. Morgan Stanley restated an “overweight” rating on shares of Smith & Nephew SNATS in a report on Wednesday, August 5th. Finally, Kepler Capital Markets cut Smith & Nephew SNATS from a “buy” rating to a “hold” rating in a report on Thursday, June 4th. Two analysts have rated the stock with a Buy rating, six have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $30.93.

Smith & Nephew SNATS Trading Up 0.1%

NYSE:SNN opened at $29.29 on Monday. The company has a current ratio of 2.14, a quick ratio of 1.11 and a debt-to-equity ratio of 0.62. Smith & Nephew SNATS, Inc. has a 1-year low of $28.56 and a 1-year high of $38.79. The stock has a fifty day simple moving average of $30.32 and a 200 day simple moving average of $31.85.

Smith & Nephew SNATS Announces Dividend

The company also recently disclosed a dividend, which will be paid on Friday, November 6th. Shareholders of record on Friday, October 2nd will be paid a dividend of $0.312 per share. The ex-dividend date of this dividend is Friday, October 2nd. This represents a yield of 205.0%.

About Smith & Nephew SNATS

Smith & Nephew plc is a global medical technology company specializing in the design, development and manufacture of advanced surgical devices, orthopaedic reconstruction implants, trauma and extremities products, sports medicine solutions and wound care therapies. Founded in 1856 in Hull, United Kingdom, the company has grown through both organic innovation and strategic acquisitions to offer a broad portfolio that addresses patient needs across joint replacement, minimally invasive surgery and wound healing.

In its orthopaedics business, Smith & Nephew provides hip and knee replacement systems, modular joint revision implants and biologic solutions for bone repair.